Inovio Faces Class Action Lawsuit Over Regulatory Disclosures

2026-04-10 07:43:37

Abstract generation in progress

Inovio Pharmaceuticals is facing a class action lawsuit filed by Bragar Eagel & Squire, P.C., alleging the company made false and misleading statements about the regulatory prospects of its INO-3107 treatment. The lawsuit claims Inovio overstated the treatment’s regulatory outlook and eligibility for accelerated FDA approval, leading to a stock price drop after the FDA accepted the BLA on a standard review timeline. Investors have until April 7, 2026, to join as lead plaintiffs in the lawsuit.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.